Trial Profile
A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo compared to standard of care insulin, in basal insulin treated patients with uncontrolled type 2 diabetes mellitus, with six month extension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin; Insulin degludec; Insulin detemir
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REGAIN; REGAIN CONTROL
- Sponsors Sanofi
- 25 Sep 2020 Results from real-world studies ACHIEVE, REACH, REGAIN, and RCTs EDITION 1-3 and BRIGHT assessing Treatment satisfaction in people with type 2 diabetes receiving basal insulin, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 18 Nov 2017 This trial has been completed in Finland (2017-10-20).
- 31 Oct 2017 Status changed from active, no longer recruiting to completed.